Bronstein, Gewirtz and Grossman, LLC announces an investigation of Agenus Inc. and urges investors to contact the firm!

NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. (“Agenus” or “the Company”) (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist in the investigation by visiting the Company’s website: bgandg.com/AGEN.

Examination details

On July 18, 2024, Agenus issued a press release announcing “the results of its End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to advance its immunotherapy combination of botensilimab (BOT) and balstilimab (BAL) for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) without active liver metastases (NLM).” The press release stated that “the FDA advised against submitting these results in support of accelerated approval because it believes objective response rates may not translate into a survival benefit.”

Due to this news, Agenus’ share price fell sharply in intraday trading on July 18, 2024.

What’s next?

If you are aware of facts related to this investigation, or if you purchased securities of Agenus, you may assist this investigation by visiting the firm’s website at bgandg.com/AGEN. You may also contact Peretz Bronstein or his account executive Nathan Miller of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.

There are no costs for you

We represent investors in class action lawsuits on a contingency basis, meaning we ask the court to reimburse us for our expenses and attorney fees (usually a percentage of the total award) only if we win.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm representing investors in securities fraud class action lawsuits and shareholder actions involving derivatives trading. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Past results do not guarantee similar results.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | (email protected)

SOURCE: Bronstein, Gewirtz & Grossman, LLC